259 related articles for article (PubMed ID: 27296828)
1. Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability.
Fan VS; Gylys-Colwell I; Locke E; Sumino K; Nguyen HQ; Thomas RM; Magzamen S
Respir Med; 2016 Jul; 116():100-6. PubMed ID: 27296828
[TBL] [Abstract][Full Text] [Related]
2. Poor Metered-Dose Inhaler Technique Is Associated with Overuse of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease.
Griffith MF; Feemster LC; Donovan LM; Spece LJ; Krishnan JA; Lindenauer PK; McBurnie MA; Mularski RA; Au DH
Ann Am Thorac Soc; 2019 Jun; 16(6):765-768. PubMed ID: 30763114
[No Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
[TBL] [Abstract][Full Text] [Related]
4. Chronic obstructive pulmonary disease: prevalence, characteristics, and pharmacologic treatment in nursing home residents with cognitive impairment.
Zarowitz BJ; O'Shea T
J Manag Care Pharm; 2012 Oct; 18(8):598-606. PubMed ID: 23127147
[TBL] [Abstract][Full Text] [Related]
5. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
[TBL] [Abstract][Full Text] [Related]
6. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
7. Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators.
Kitaguchi Y; Fujimoto K; Komatsu Y; Hanaoka M; Honda T; Kubo K
Respir Med; 2013 Mar; 107(3):394-400. PubMed ID: 23245993
[TBL] [Abstract][Full Text] [Related]
8. Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.
Ghosh S; Anderson WH; Putcha N; Han MK; Curtis JL; Criner GJ; Dransfield MT; Barr RG; Krishnan JA; Lazarus SC; Cooper CB; Paine R; Peters SP; Hansel NN; Martinez FJ; Drummond MB;
Ann Am Thorac Soc; 2019 Feb; 16(2):200-208. PubMed ID: 30216731
[TBL] [Abstract][Full Text] [Related]
9. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.
Sharafkhaneh A; Altan AE; Colice GL; Hanania NA; Donohue JF; Kurlander JL; Rodriguez-Roisin R; Altman PR
Respir Med; 2014 Sep; 108(9):1310-20. PubMed ID: 25130680
[TBL] [Abstract][Full Text] [Related]
10. Switching treatments in COPD: implications for costs and treatment adherence.
Braido F; Lavorini F; Blasi F; Baiardini I; Canonica GW
Int J Chron Obstruct Pulmon Dis; 2015; 10():2601-8. PubMed ID: 26664108
[TBL] [Abstract][Full Text] [Related]
11. [Persistence to treatment by type of inhaler device in patients with asthma and chronic obstructive pulmonary disease].
Sicras A; Ferrer V; Collar JM; Navarro R; Sáez M
Semergen; 2017; 43(5):375-386. PubMed ID: 27425817
[TBL] [Abstract][Full Text] [Related]
12. Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators.
Keshishian A; Xie L; Dembek C; Yuce H
Clin Ther; 2019 Nov; 41(11):2283-2296. PubMed ID: 31630815
[TBL] [Abstract][Full Text] [Related]
13. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
15. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
[TBL] [Abstract][Full Text] [Related]
16. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
17. Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study.
Alzaabi A; Bell JP; Montero-Arias F; Price DB; Jackson DJ; Wang HC; Budgen N; Farouk H; Maslova E
Adv Ther; 2023 Nov; 40(11):4836-4856. PubMed ID: 37684493
[TBL] [Abstract][Full Text] [Related]
18. Association of ambient pollution with inhaler use among patients with COPD: a panel study.
Magzamen S; Oron AP; Locke ER; Fan VS
Occup Environ Med; 2018 May; 75(5):382-388. PubMed ID: 29535158
[TBL] [Abstract][Full Text] [Related]
19. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
Wurst KE; Shukla A; Muellerova H; Davis KJ
COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
[TBL] [Abstract][Full Text] [Related]
20. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy.
Bollu V; Ejzykowicz F; Rajagopalan K; Karafilidis J; Hay JW
J Med Econ; 2013 Aug; 16(8):1082-8. PubMed ID: 23777224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
